KKKiran Reddy Kanubaddi

Kiran Reddy Kanubaddi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kiran Reddy Kanubaddi has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Ai-Zheng Chen

    Institute of Biomaterials and Tissue Engineering, Huaqiao University, Xiamen, China

    1 shared publication
  • Chen-Guang Liu

    The affiliated 903 Hospital of Zhejiang Sci‐Tech University, Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, Zhejiang Provincial Key Laboratory of Drug Discovery and Development for Metabolic Diseases College of Life Sciences and Medicine Hangzhou Zhejiang Province China

    1 shared publication
  • Chia-Hung Lee

    Department of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien 97401, Taiwan,

    1 shared publication
  • Chia‐Hung Lee

    Department of Life Science and Institute of Biotechnology National Dong Hwa University Hualien 97401 Taiwan

    1 shared publication
  • Ching-Feng Weng

    Department of Physiology, School of Basic Medical Sciences, Key Laboratory of Functional and Clinical Translational Medicine, Fujian Province University, Xiamen Medical College, Xiamen 361023, China

    1 shared publication
  • Helder Almeida Santos

    Department of Biomaterials and Biomedical Technology The Personalized Medicine Research Institute (PRECISION) University Medical Center Groningen University of Groningen Groningen The Netherlands

    1 shared publication

Latest Publications

  • Metal Species–Encapsulated Mesoporous Silica Nanoparticles: Current Advancements and Latest Breakthroughs

    by Ranjith Kumar Kankala, Hongbo Zhang, Chen‐Guang Liu, Kiran Reddy Kanubaddi, Chia‐Hung Lee, Shi‐Bin Wang, Wenguo Cui, Hélder A. Santos, KaiLi Lin, Ai‐Zheng Chen

    Despite their advantageous morphological attributes and attractive physicochemical properties, mesoporous silica nanoparticles (MSNs) are merely supported as carriers or vectors for a reason. Incorporating various metal species in the confined nanospaces of MSNs (M‐MSNs) significantly enriches their mesoporous architecture and diverse functionalities, bringing exciting potentials to this burgeoning field of research. These incorporated guest species offer enormous benefits to the MSN hosts concerning the reduction of their eventual size and the enhancement of their performance and stability, among other benefits. Substantially, the guest species act through contributing to reduced aggregation, augmented durability, ease of long‐term storage, and reduced toxicity, attributes that are of particular interest in diverse fields of biomedicine. In this review, the first aim is to discuss the current advancements and latest breakthroughs in the fabrication of M‐MSNs, emphasizing the pros and cons, the confinement of various metal species in the nanospaces of MSNs, and various factors influencing the encapsulation of metal species in MSNs. Further, an emphasis on potential applications of M‐MSNs in various fields, including in adsorption, catalysis, photoluminescence, and biomedicine, among others, along with a set of examples is provided. Finally, the advances in M‐MSNs with perspectives are summarized.


  • Open Access

    Nanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation

    by Kiran Reddy Kanubaddi, Shin-Han Yang, Li-Wei Wu, Chia-Hung Lee, Ching-Feng Weng

    Alzheimer’s disease (AD), an age-related neurodegenerative disease, the most common causes of dementia is a multifactorial pathology categorized by a complex etiology. Numerous nutraceuticals have been clinically evaluated, but some of the trials failed. However, natural compounds have some limitations due to their poor bioavailability, ineffective capability to cross the blood–brain barrier, or less therapeutic effects on AD. To overcome these disadvantages, nanoparticle-conjugated natural products could promote the bioavailability and enhance the therapeutic efficacy of AD when compared with a naked drug. This application generates and implements new prospect for drug discovery in neurodegenerative diseases. In this article, we confer AD pathology, review natural products in clinical trials, and ascertain the importance of nanomedicine coupled with natural compounds for AD.